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Adrenal insufficiency (AI) is classified according to aprimary adrenal cause or as a consequence of central
AI [which can be divided into secondary AI (SAI) and
tertiary AI (TAI)] (1). SAI is caused by the loss of corti-
cotroph cell function, most frequently by pituitary tumors
and/or their subsequent treatment including surgery and
radiotherapy (2). By contrast, TAI occurs due to sup-
pression of corticotroph function following exogenous
glucocorticoid (GC) therapy and is a major unmet clinical
needwith 0.5% to 2%of the population taking exogenous
GC therapy to treat a variety of inflammatory diseases (3).
Hypothalamic-pituitary-adrenal axis suppression by ex-
ogenous GCs has been associated with adrenal crisis in
patients treated with systemic, inhaled, intra-articular and
topicalGCs (4, 5) and is related to the cumulative exposure
(determined by a combination of the duration of therapy
and the dose and relative potency of GC used). However,
there is considerable interindividual variability in the re-
sponse to GCs and as such any consensus to what defines
the level of exposure required to cause AI is difficult.
The short synacthen test (SST) is now the most
widely used method of assessment of adrenal sufficiency.
Tetracosactrin, a synthesized polypeptide with an amino
acid sequence including 1 to 24 of the 1 to 39 chain of the
naturally occurring corticotropin, has adrenocortical
stimulatory action equivalent to that of natural corti-
cotropin (6).With adrenal reserve post exogenous ACTH
dictated by the prevailing level of endogenous ACTH, a
number of studies have shown that the SST performs well
when compared with the originally described “gold
standard” insulin tolerance test (ITT) in assessing AI/
sufficiency (7, 8). However, it is important to note that
such studies have predominantly assessed GC sufficiency
in an at-risk population of AI rather than recovery of
adrenal function in patients with established AI. In the
former studies peak cortisol pass/fail values across an SST
have been validated against an ITT; basal random cor-
tisol concentrations and incremental change post-SST
have been unhelpful discriminators.
Here the study by Pofi et al. (9) is a useful addition to
the literature reporting results of synacthen testing from a
large retrospectively studied cohort of patients with cen-
tral AI, comprising both SAI (n = 776) and TAI (n = 110),
from three academic endocrine centers. It is important to
make the distinction between patients with SAI and TAI in
this study as the potential for recovery of adrenal function
(and thus pre-test probability of recovery) are significantly
different in each group but overall across the entire cohort
of 886 patients, 37% of patients who initially failed an
SST eventually went on to subsequently pass an SST.
In the pituitary disease group of patients with SAI,
57% of patients with nonfunctioning pituitary tumors
and 44% of patients who underwent pituitary surgery
subsequently passed the SST. This is significantly higher
than one would have expected and has major potential
implications for clinical practice. Although untreated or
unrecognized AI confers the risk of adrenal crisis and
increased morbidity and mortality, it has also become
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increasingly evident that morbidity and mortality are
increased in patients with AI taking replacement GC
(10–16). The mortality excess is largely due to increased
cardiovascular deaths (15), most likely from subtle but
prolonged increase in either dose of GC replacement
and/or a noncircadian mode of replacement, effectively
leading to mild Cushing syndrome (17). Impaired quality
of life is a further major issue that again appears to be
related to AI but also GC exposure (18, 19). The re-
alization that many patients with established SAI might
recover endogenous adrenal function and thereby avoid
lifelong GC replacement is clearly important.
In patients with SAI, the 30-minute cortisol response
post-SST was the best indicator of future (and more
prompt) adrenal recovery, but accuracy of predicting
future recovery of adrenal function was further enhanced
by combining the 30-minute cortisol SST value with the
baseline cortisol (which can be taken as being equivalent
to a random morning cortisol). In the TAI group it was
the delta cortisol across the SST (the difference between
the baseline and 30-minute sample) that was the best
predictor for future adrenal recovery. Combining the
delta cortisol threshold with a subsequent random cor-
tisol (above or below 200 nmol/L) helped to refine the
predictive ability of the test.
The paper has some limitations, which the authors
highlight, including the retrospective nature of the study,
potential selection bias, and lack of data regarding GC
exposure.
The diagnostic cutoffs of a “normal” cortisol response
to dynamic testing including SST have been debated for
some time. The ITT “pass” value was originally defined
as the minimum cortisol response required to safely
undergo a stressful event (elective surgery) (20). With the
emergence of immunoassays, it was found that the
previously used fluorometric assays overestimated the
cortisol response to synacthen due to lack of assay
specificity and cross-reactivity with other GCs (cortico-
sterone and cortisone). The advent of modern radioim-
munoassay and the demonstration of a close correlation
between the ITT and the SST further reinforced the view
that the commonest thresholds used to indicate normal
function should be approximately .500 nmol/L or
550 nmol/L (8, 21) and with newer assays as low as
450 nmol/L (22). This study uses three different assays
(including two different generations of the same assay
system), which have significantly different cutoffs for
passing the SST and although the authors have attempted
to control for this, it remains a potential factor that
should be taken into account when interpreting the data.
Importantly, when assessing any cutoff for the SST, the
assay used and assay specific cutoff for cortisol on an SST
must be defined. There is substantial interassay variation
in cortisol assays; Klose et al. (22) and more recently El-
Farhan et al. (23) demonstrated that individual samples
may differ by up to 50 to 110 nmol/L when measured by
different assays. Similarly, Clarke et al. (24) have shown
substantial gender differences in healthy controls when
assessing cortisol response to SST depending on the
assay used.
As well as the utility of the peak cortisol value post-
SST, the authors highlight the importance of the delta
cortisol to predict future recovery of AI. It is perhaps not
surprising that in a group of patients with suppressed
adrenal function post exogenous GC therapy as opposed
to a “normal” population being evaluated for adrenal
sufficiency, the incremental change in cortisol was clin-
ically useful. However, it is important to stress that the
SST in this context has yet to be validated against the ITT;
Kane et al. (25) in a small series of GC treated rheu-
matology patients highlighted differences between the
performance of the SST and ITT in patients with TAI;
8/22 patients failing the SST but passed the ITT.
Another key factor in interpreting this data are that
patients with hypopituitarism and pituitary tumors are a
very heterogenous group with differences in tumor size,
tumor invasiveness, degree of surgical intervention, de-
gree of hypopituitarism, and dose of hydrocortisone
therapy prescribed. All of these factors may impact on the
possibility of subsequent recovery of adrenal function;
for example, if ACTH was the only deficiency and there
was no gonadotropin or GH deficiency, one might be
suspicious that this was not a true initial SST fail, given
the hierarchy of pituitary hormone deficits that is often
encountered. Clinical data are lacking on the charac-
teristics of the SAI group; more studies are required
with greater clinical details before generalizing to other
populations.
The significant rates of recovery of adrenal function in
the pituitary patient group is intriguing. Arafah et al. (26)
initially studied this concept in 1994 and postulated that
recovery in AI following pituitary surgery could be due
to a decrease in compression of the portal vessels lead-
ing to an improved delivery of hypothalamic hor-
mones. Although there have been reports of recovery of
hypothalamic-pituitary-adrenal function in SAI, the per-
cent recovery rate here is surprising. Munro et al. (27),
albeit in a smaller cohort, reported recovery of SAI in
17.6% during follow-up. There may be a potential se-
lection bias; it would not be routine practice to repeat
dynamic testing in patients labeled with SAI without
additional indication that recovery was possible. It is not
clear what the indications for this repeat testing
were in this particular study. Similarly, the authors ad-
vocate that patients with SAI who have a 30-minute
cortisol .350 nmol/L should have repeat testing every
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6 months. In contrast, the ,350 nmol/L cohort had a
much slower recovery and an annual testing strategy
could be adopted. There may be bias here, in that the
timing of the repeat testing was left to individual clini-
cians’ discretion and was not part of a protocolized
pathway, and as such patients who had lower 30-minute
values may not have been tested as frequently or early.
Despite these limitations the use of the peak cortisol
value post-SST with or without the additional predictive
value of a basal cortisol sample and incremental response
during SST may be very helpful in predicting the chance
of future recovery of adrenal function. This should
encourage a lower threshold for further retesting in
patients with both SAI and TAI but may also prevent
unnecessary SSTs when there is little chance that the
patient will pass a subsequent SST. This study will need
to be supported by prospective data but raises important
clinical practice issues, particularly given the GC-related
increased morbidity and mortality of patients with SAI
and TAI.
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